Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Protodioscin is a naturally occurring furostanol saponin found in several plant species, most notably *Tribulus terrestris*, *Dioscorea* (yam), and *Trigonella*. It is widely recognized as a dietary supplement ingredient rather than a regulated pharmaceutical drug. Research has explored its potential in various therapeutic areas, including oncology (where it was screened by the National Cancer Institute as NSC-698796), hyperlipidemia, and sexual dysfunction. Its biological effects are attributed to the stimulation of nitric oxide release, activation of Na+/K+ ATPase and Ca2+/Mg2+ ATPase, and potential modulation of androgen levels. While it has shown activity against several human cancer cell lines, including leukemia, colon, and prostate cancer in research settings, it remains primarily in the realm of nutraceuticals and research without a formal pharmaceutical developer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on protodioscin.